Download Free Sample
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....
US Multiple Sclerosis Market: By Drug Class, By Route of administration, By Distribution Channel and Country
US Multiple Sclerosis Market: By Drug Class, By Route of administration, By Distribution Channel and Country
US Multiple Sclerosis Market size was valued at US$ 13,957.7 million in 2023 and is expected to grow at a 6.2% CAGR from 2024 to 2030. Multiple sclerosis is an immune-related disease affecting the central nervous system. Multiple sclerosis is a chronic demyelinating disease in the central nervous system that may significantly cause disability in adults. The inflammation and scarring of myelin sheaths covering the nerves causes multiple sclerosis. The increasing prevalence of multiple sclerosis has increased the demand for effective diagnosis and treatment of multiple sclerosis in the US. According to National Multiple Sclerosis Society USA, approximately 1 million people are living with Multiple Sclerosis in the United States.
Multiple sclerosis prevalence has increased in every region since 2013 .The government is also supporting the treatment of multiple sclerosis by raising funds and creating awareness in the public. The key drivers in the growth of the market are increasing focus on research and development in order to develop innovative drugs in the market. The major challenge in this treatment is the unknown etiology of the disease which is expected to hinder the market growth in the forecasted period. However, the growing focus of companies on the pipeline drugs for multiple sclerosis is also boosting the multiple sclerosis market growth in US. Biogen, a leading pharmaceutical company in theUS has been developing orelabrutinib, and currently is in the clinical trial phase 2. Moreover, Novartis has been developing remibrutinib which is also currently in the clinical trial phase 3 for the treatment of multiple sclerosis.
The market is growing due to the increasing prevalence of multiple sclerosis has increased the demand for effective diagnosis and treatment of multiple sclerosis in US. Huge investments done by the key players in research and development of the innovative drugs drives the market in the region. In addition, the government also supporting in the treatment of multiple sclerosis in this region. The introduction of disease modifying drug is expected to fuel the market growth in the forecasted period. The immunomodulators are expected to grow at a significant rate in the forecasted period.
|
Report Benchmarks |
Details |
|
Market Size in 2023 |
US$ 13,957.7 million |
|
By Drug class |
|
|
By Route of administration |
|
|
By Distribution channel |
|
|
By Region |
|
Download Free Sample Report
The global us multiple sclerosis market size was valued at US$ 13,957.7 million in 2023 and is projected to grow at a CAGR of 6.2% from 2024 to 2030..
The key driving factors of the US multiple sclerosis market is increase in prevalence on multiple sclerosis and the rising investment of key player in research and development for the innovation of new drugs.
The leading players in the global US Multiple sclerosis market are Biogen, Pfizer Inc., F. Hoffmann-La Roche Ltd., Novartis AG, Merck & Co, Sanofi, Teva Pharmaceuticals, Jansenn Pharmaceuticals Inc., Bristol-Meyers Squibb Company
Historic years considered for the market study are 2018 through 2022, 2022 is considered as the base year for market estimation and Seven years forecast presented from 2023– 2029.
| 1.Executive Summary |
| 2. US Multiple Sclerosis Market Introduction |
| 2.1. US Multiple Sclerosis Market - Taxonomy |
| 2.2. US Multiple Sclerosis Market - Definitions |
| 2.2.1.Drug class |
| 2.2.2.Route of administration |
| 2.2.3.Distribution channel |
| 3. US Multiple Sclerosis Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Product Landscape |
| 3.6. New Product Launches |
| 3.7. Impact of COVID 19 on Market |
| 4. US Multiple Sclerosis Market Analysis, 2019 - 2023 and Forecast 2024 - 2030 |
| 4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5. US Multiple Sclerosis Market By Drug class, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 5.1. Immunomodulators |
| 5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. Immunosuppressants |
| 5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 5.3. Interferons |
| 5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.3. Market Opportunity Analysis |
| 5.4. Others |
| 5.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.4.3. Market Opportunity Analysis |
| 6. US Multiple Sclerosis Market By Route of administration, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 6.1. Oral |
| 6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. Intravenous |
| 6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 6.3. Intramuscular |
| 6.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.3.3. Market Opportunity Analysis |
| 6.4. Subcutaneous |
| 6.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.4.3. Market Opportunity Analysis |
| 7. US Multiple Sclerosis Market By Distribution channel, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 7.1. Hospital Pharmacy |
| 7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. Retail Pharmacy |
| 7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 7.3. Online Pharmacy |
| 7.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.3.3. Market Opportunity Analysis |
| 8. Competition Landscape |
| 8.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
| 8.2.1.Biogen |
| 8.2.2.Pfizer Inc. |
| 8.2.3.F. Hoffmann-La Roche Ltd. |
| 8.2.4.Novartis AG |
| 8.2.5.Merck & Co |
| 8.2.6.Sanofi |
| 8.2.7.Teva Pharmaceuticals |
| 8.2.8.Jansenn Pharmaceuticals Inc. |
| 8.2.9.Bristol-Meyers Squibb Company |
| 9. Research Methodology |
| 10. Appendix and Abbreviations |
Key Market Players
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthcare domain, encompassing pharmaceuticals, medical devices, and diagnostics. A graduate in Pharmacy, he possesses a strong foundation in the intricacies of the healthcare sector. He further enhanced his expertise by pursuing an MBA in Pharmaceuticals, equipping him with valuable business acumen. His analytical skills and market insights have contributed to strategic decision-making and enhanced market positioning for various healthcare organizations. Committed to driving innovation and excellence, Muni continues to seek opportunities to improve healthcare delivery through data-driven insights.